



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 16 2010

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Christian Smolizza, Esq.
Pfizer Inc.
Patent Department (150/05/43S)
150 East 42nd Street
New York, NY 10017-5755

In Re: Patent Term Extension
Application for
U.S. Patent No. 6,667,314

Dear Ms. Smolizza:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 6,667,314 for a period of 73 days. While a courtesy copy of this letter is being forwarded to the Food and Drug Administration (FDA), you should directly correspond with the FDA regarding any required changes to the patent expiration dates set forth in the Patent and Exclusivity Data Appendix of the Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) or in the Patent Information set forth in the Green Book (FDA Approved Animal Drug Products). Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from FDA's Electronic Forms Download Website:

<http://www.fda.gov/opacom/morechoices/fdaforms/default.html>
(<http://www.fda.gov/opacom/morechoices/fdaforms/FDA-3542.pdf>).

Inquiries regarding this communication should be directed to Raul Tamayo by telephone at (571) 272-7728, or by e-mail at raul.tamayo@uspto.gov.

Mary C. Till

Legal Advisor

Office of Patent Legal Administration

Office of the Associate Commissioner

for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: SELZENTRY® (maraviroc)
Docket No.: FDA-2008-E-0194

Attention: Beverly Friedman

UNITED STATES PATENT AND TRADEMARK OFFICE

(12) CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

(68) PATENT NO. : 6,667,314
(45) ISSUED : December 23, 2003
(75) INVENTOR : Manoussos Perros et al.
(73) PATENT OWNER : Pfizer Inc.
(95) PRODUCT : SELZENTRY® (maraviroc)

This is to certify that an application under 35 U.S.C. § 156 has been filed in the United States Patent and Trademark Office, requesting extension of the term of U.S. Patent No. 6,667,314 based upon the regulatory review of the product SELZENTRY® (maraviroc) by the Food and Drug Administration. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

(94) 73 days

from May 25, 2021, the original expiration date of the patent, subject to the payment of maintenance fees as provided by law, with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the United States Patent and Trademark Office to be affixed this 11th day of June 2010.

David J. Kappos

David J. Kappos
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office